This web site is not optimized for Internet Explorer 6. You may notice
decreased functionality compared to other web browsers. Please follow the
link below to upgrade to a new version of Internet Explorer.

The "Yes" link below will take you out of the Abbott Laboratories family of websites.
Links which take you out of Abbott Laboratories worldwide web sites are not under the
control of Abbott Laboratories, and Abbott Laboratories is not responsible for the
contents of any such site or any further links from such site. Abbott Laboratories is
providing these links to you only as a convenience, and the inclusion of any link does
not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?
 
Coronary Drug Eluting Stents

XIENCE V Everolimus Eluting Coronary Stent System

Indications & Important Safety Information ››
 

banner

Healthcare Professionals

Healthcare Professionals

XIENCE V - a DES with superior* outcomes that can take your performance to new heights. Abbott'€™s XIENCE V is truly a next-generation DES, combining the proven deliverability of the MULTI-LINK VISION stent platform with a Multi-layer Coating Technology and everolimus to deliver superior* outcomes for patients with coronary artery disease (CAD).

Learn about the proven design of XIENCE V: Deliverable, Effective, and Safe

* XIENCE V has demonstrated statistical superiority against Taxus Express in the primary endpoints of SPIRIT IV, SPIRIT III and SPIRIT II in target lesion failure, in-segment late loss and in-stent late loss respectively. Source: SPIRIT II Angiographic  6 months follow-up, Serruys. P, EuroInterv 2006; 2:286-294. SPIRIT III Angiographic  8months follow-up, Gregg Stone, JAMA 2008; 299(16): 1903-1913. SPIRIT IV 1-year results, Gregg Stone, TCT 2009 and data on file at Abbott Vascular.  

TAXUS, TAXUS Liberte, and TAXUS Express are registered trademarks of Boston Scientific  or its affiliates.

SPIRIT IV 1 YR

 

SPIRIT III 3 YR Results

 

spirit iv 1 yr

 

ARC Stent Thrombosis, Cardiac Death, and Target Vessel MI figures are binominal. All other data from Kaplan Meier curves.

TLF (Target Lesion Failure) = cardiac death, target vessel MI, or ID-TLR. TLF was prespecified for superiority testing.


Learn about the benefits of proven design

 Reference
1. Source: SPIRIT IV 1-year results, Gregg Stone, TCT 2009.

SPIRIT III 3 YR

 

SPIRIT IV 1-Year Results

 

spirit iii 3 yr

ARC Stent Thrombosis figures are binomial. Other data from Kaplan Meier curves. MACE = cardiac death, MI, ID-TLR by CABG, or PCI.


Learn about the benefits of proven design

References
1. Source: SPIRIT III 3-year results, Gregg Stone, TCT 2009.

Taxus Express was the control in SPIRIT III.

Proven Design

XIENCE V is the DES designed for deliverability, efficacy, and safety. Every element of the stent and delivery system has been evaluated to bring you a true next-generation DES.

thin struts for less injury  Thin struts for less injury1
  • 0.0032" strut thickness2
  • Clinically proven MULTI-LINK VISION CoCr stent
  • World's #1 metallic stent3
 superb deliverability Superb deliverability
  • Low balloon outside the stent to reduce injury4, 5
 controlled release, low dose of everolimus Controlled release, low dose of everolimus
  • Cytostatic drug
 Multi-layer Coating Technology Multi-layer Coating Technology
  • Thin, durable

 

1Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-II) trial. JACC. 2003; 41(8).
2Manufacturer-reported strut thickness. Data on file at Abbott Vascular.
3Market Share data on file as of March 2012.
4Tests performed by and data on file at Abbott Vascular.
5Carter, A.J. Experimental evaluation of a short transitional edge protection balloon for intracoronary stent deployment. CCI. 2000;51:112-119.

Hospital Administrators

XIENCE V provides superior* outcomes.
Combining Abbott'€™s strong legacy of leadership and innovation with excellent service and support, XIENCE V delivers a solution that you can deploy with confidence.


The best possible customer service
Abbott is dedicated to offering hospitals the support they need to find products and answer questions. Below are resources designed just for you.

Country Customer Service Contact Phone Number
Sweden 46 (0) 8 546 56 951
Finland 46 (0) 8 546 56 951
Norway 46 (0) 8 546 56 952
Denmark 46 (0) 8 546 56 952
Austria 43 1 89122458
UK 44 1628 774 968
Italy 39 02 51 625 130
Spain 34 9 13370687
Germany 49 800 1 80 81 93
France 01 47 14 40 05

South Asia (India, Pakistan,

Bangladesh, Sri Lanka)

91 11 4053 0113
Australia +61 1800 550 939
Hong Kong +852-2593-2288
India +91-11-5162-8547

 

*XIENCE V has demonstrated statistical superiority against Taxus Express in the primary endpoints of SPIRIT IV, SPIRIT III and SPIRIT II in target lesion failure, in-segment late loss and in-stent late loss respectively. Source: SPIRIT IV 1-year results, Gregg Stone, TCT 2009 and data on file at Abbott Vascular.  
TAXUS, TAXUS Liberte, TAXUS Express2 are registered trademarks of Boston Scientific  or its affiliates.

AP2936764-OUS Rev. C

 

Indications and Important Safety Information

Top

Top